Dasatinib and quercetin pilot study assessed safety in older adults at Alzheimer's risk.
This pilot study tested the safety and feasibility of intermittent dasatinib and quercetin dosing in older adults at risk of Alzheimer's disease. The study aimed to evaluate whether the treatment might improve cerebral blood flow, mobility, and cognition. Results of the trial outcomes are not reported in the abstract.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Mar 17, 2025 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Other
- Sample size
- —
- Duration
- —
- Population
- Older adults at risk of Alzheimer's disease
- Primary outcome
- Safety and feasibility of administering intermittent doses of Dasatinib and Quercetin in older adults at risk of Alzheimer's disease
- Effect size
- —
- Significance
- Not reported
- Journal
- Lewis Lipsitz
- Published
- Mar 17, 2025
Sources
Primary source
- Lewis Lipsitz ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.